RRC ID 64020
Author Satomi H, Wang B, Fujisawa H, Otsuka F.
Title Interferon-beta from melanoma cells suppresses the proliferations of melanoma cells in an autocrine manner.
Journal Cytokine
Abstract Interferon (IFN)-alpha and IFN-beta have been utilized in the treatment of melanoma as a form of cytokine therapy. While previous studies have demonstrated that melanocytes and melanoma cells produce a number of cytokines, it remains unclear whether or not melanocytes and melanoma cells per se produce IFN-alpha or IFN-beta. In the present study, we investigated the expression of IFN-alpha or IFN-beta in human melanocytes and five melanoma cell lines: G-361, C32TG, MMAc, MEWO and VMRC-MELG at both mRNA and protein levels. Both IFN-alpha and IFN-beta mRNA were detected in normal human melanocytes. Likewise, IFN-alpha mRNA was detected in all five melanoma cell lines. However, IFN-beta mRNA was only detected in one melanoma cell line, VMRC-MELG. When melanocytes and melanoma cells were treated with a potent IFN inducer, polyinosinic:polycytidylic acid (poly I:C), the mRNA expression of both IFN-alpha and IFN-beta was significantly upregulated. Poly I:C was not able to induce melanocytes or melanoma cells to produce detectable amounts of IFN-alpha protein, but able to induce a significant amount of IFN-beta in melanocytes and two of the melanoma cell lines: MMAc and VMRC-MELG. Moreover, similar to exogenous IFN-alpha and IFN-beta, poly I:C significantly inhibited the proliferation of all five melanoma cell lines. This suppressive effect was partially blocked by anti-IFN-beta antibody treatment in the IFN-beta-producing melanoma cell lines: MMAc and VMRC-MELG, but not in the non-IFN-beta-producing cell lines: G-361, C32TG and MEWO. Collectively, these studies have demonstrated for the first time that human melanocytes and melanoma cells produce IFN-beta. Furthermore, melanoma cells are capable of suppressing their own proliferation via secretion of endogenous IFN-beta. This finding may have important implications for melanoma therapy.
Volume 18(2)
Pages 108-15
Published 2002-4-21
DOI 10.1006/cyto.2002.1028
PII 10.1006/cyto.2002.1028
PMID 12096926
MeSH Cell Division / drug effects* Cells, Cultured DNA Primers Humans Infant, Newborn Interferon-alpha / genetics Interferon-beta / genetics* Interferon-beta / pharmacology* Lipopolysaccharides / pharmacology* Melanocytes / drug effects Melanocytes / immunology Melanoma / genetics Melanoma / immunology Melanoma / pathology* Poly I-C / pharmacology Polymerase Chain Reaction Transcription, Genetic Tumor Cells, Cultured
IF 2.952
Human and Animal Cells MMAc(RCB0808)